GlassScriptPhysician profile
Daniel Aaron Jones
NPI 1073273462
$5,444.08
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,465 · 2023: $2,265 · 2024: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,979.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,343.49 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $460.40 | 2022-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $440.34 | 2022-2024 | Entyvio, Gattex |
| Nestle Healthcare Nutrition INC. | $255.24 | 2022-2023 | |
| Qol Medical, LLC | $199.64 | 2022-2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $196.51 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $181.01 | 2022-2023 | Ocaliva |
| Janssen Biotech, INC. | $174.40 | 2022-2023 | Stelara |
| Gilead Sciences, INC. | $166.32 | 2022-2024 | |
| Ardelyx, INC. | $164.14 | 2022-2023 | Ibsrela |
| Organon LLC | $144.04 | 2022-2024 | Renflexis, Hadlima |
| Genzyme Corporation | $135.95 | 2022-2024 | |
| Celgene Corporation | $125.21 | 2022-2023 | Zeposia |
| Braintree Laboratories, INC. | $76.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.02 | 2023 | Cyltezo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $61.09 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $60.42 | 2022-2023 | Injectafer |
| Mylan Institutional INC. | $54.92 | 2023 | Hulio |
| Redhill Biopharma INC. | $48.50 | 2022 | |
| Ferring Pharmaceuticals INC. | $26.61 | 2022 | |
| Fresenius Kabi USA, LLC | $23.52 | 2023 | |
| Aimmune Therapeutics, INC. | $15.80 | 2024 | |
| Phadia US INC. | $14.16 | 2024 | Immunocap |
| Idorsia Pharmaceuticals US INC | $13.05 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.